Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Biomarker highlights from ASCO GU

Felix Feng • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Docetaxel
RTOG-9601

Felix Feng, MD, University of California San Francisco, San Francisco, CA, discusses the key areas of radiation oncology research in the field of genitourinary (GU) cancer. Prof. Fang highlights the performance of biomarkers, specifically the use of decipher in the RTOG-9601 study (NCT00002874) and the PAM50 classifier. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Felix Feng

1:14
Prostate cancer: biomarkers
Felix Feng • 13 Feb 2020
1:37
Genomic prognostics in PC salvage radiation
Felix Feng • 13 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals